{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T18:40:44Z","timestamp":1683052844838},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1007\/s00393-005-0695-7","type":"journal-article","created":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T20:15:41Z","timestamp":1111695341000},"page":"102-110","source":"Crossref","is-referenced-by-count":3,"title":["i.v.-Immunglobuline bei chronischen idiopathischen Myositiden"],"prefix":"10.1007","volume":"64","author":[{"given":"H.","family":"Michels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.-R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403?407","journal-title":"N Engl J Med"},{"key":"CR2","doi-asserted-by":"crossref","unstructured":"Burmester G-R, Buttgereit F (2001) Dermatomyositis?Polymyositis. In: Zeidler H, Zacher J, Hiepe F, editors. Interdisziplin\u00e4re klinische Rheumatologie. Springer, Berlin, S895?903","DOI":"10.1007\/978-3-662-07967-6_66"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"Dalakas","year":"1991","unstructured":"Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325(21):1487?1498","journal-title":"N Engl J Med"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (First of two parts). N Engl J Med 292(7):344?347","journal-title":"N Engl J Med"},{"key":"CR5","unstructured":"Catoggio LJ (2003) Connective Tissue Disorders: Inflammatory Muscle Disease. Management. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology. Mosby, Edinburgh, pp 1555?1562"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329(27):1993?2000","journal-title":"N Engl J Med"},{"key":"CR7","first-page":"Annex","volume":"786","author":"WHO","year":"1989","unstructured":"WHO technical report (1989) Requirements for the collection, processing, and quality control of blood, blood components, and plasma derivatives. WHO technical Report Series No 786: Annex 4","journal-title":"WHO technical Report Series No"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/(SICI)1096-9071(199709)53:1<25::AID-JMV5>3.0.CO;2-S","volume":"53","author":"Berger","year":"1997","unstructured":"Berger A, Doerr HW, Scharrer I, Weber B (1997) Follow-up of four HIV-infected individuals after administration of hepatitis C virus and GBV-C\/hepatitis G virus contaminated intravenous immunoglobulin: evidence for HCV but not for GBV-C\/HGV transmission. J Med Virol 53(1):25?30","journal-title":"J Med Virol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0149-2918(96)80198-6","volume":"18","author":"Bjorkander","year":"1996","unstructured":"Bjorkander J, Fasth A, Widell A (1996) Intravenous immunoglobulin and hepatitis C virus: the Scandinavian experience. Clin Ther 18:(Suppl B):73?82","journal-title":"Clin Ther"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJM199412153312402","volume":"331","author":"Bjoro","year":"1994","unstructured":"Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T (1994) Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 331(24):1607?1611","journal-title":"N Engl J Med"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jama.1996.03540190035026","volume":"276","author":"Bresee","year":"1996","unstructured":"Bresee JS, Mast EE, Coleman PJ, Baron MJ, Schonberger LB, Alter MJ et al (1996) Hepatitis C virus infection associated with administration of intravenous immune globulin: A cohort study. JAMA 276(19):1563?1567","journal-title":"JAMA"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2249.1997.508-ce1412.x","volume":"110","author":"Christie","year":"1997","unstructured":"Christie JM, Healey CJ, Watson J, Wong VS, Duddridge M, Snowden N et al (1997) Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol 110(1):4?8","journal-title":"Clin Exp Immunol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1081-1206(10)63416-3","volume":"76","author":"Flora","year":"1996","unstructured":"Flora K, Schiele M, Benner K, Montanaro A, Johnston W, Whitham R et al (1996) An outbreak of acute hepatitis C among recipients of intravenous immunoglobulin. Ann Allergy Asthma Immunol 76(2):160?162","journal-title":"Ann Allergy Asthma Immunol"},{"key":"CR14","first-page":"1131","volume":"18","author":"Gangneux","year":"1996","unstructured":"Gangneux JP, Traineau R, Tuveri R, Ravera N, Bureau C, Gluckman E et al (1996) Transmission of hepatitis C virus in allografted patients: use of viral genotyping as an epidemiological marker. Bone Marrow Transplant 18(6):1131?1133","journal-title":"Bone Marrow Transplant"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0149-2918(96)80192-5","volume":"18","author":"Gomperts","year":"1996","unstructured":"Gomperts ED (1996) Gammagard and reported hepatitis C virus episodes. Clin Ther 18(Suppl B):3?8","journal-title":"Clin Ther"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/gast.1996.v110.pm8613001","volume":"110","author":"Healey","year":"1996","unstructured":"Healey CJ, Sabharwal NK, Daub J, Davidson F, Yap PL, Fleming KA et al (1996) Outbreak of acute hepatitis C following the use of anti-hepatitis C virus-screened intravenous immunoglobulin therapy. Gastroenterology 110(4):1120?1126","journal-title":"Gastroenterology"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1542\/peds.98.2.211","volume":"98","author":"Jonas","year":"1996","unstructured":"Jonas MM, Baron MJ, Bresee JS, Schneider LC (1996) Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics 98(2 (Pt 1):211?215","journal-title":"Pediatrics"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1537-2995.1996.36596282581.x","volume":"36","author":"Lefrere","year":"1996","unstructured":"Lefrere JJ, Loiseau P, Martinot-Peignoux M, Mariotti M, Ravera N, Thauvin M et al (1996) Infection by hepatitis C virus through contaminated intravenous immune globulin: results of a prospective national inquiry in France. Transfusion 36(5):394?397","journal-title":"Transfusion"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood.V90.3.1309","volume":"90","author":"Rossi","year":"1997","unstructured":"Rossi G, Tucci A, Cariani E, Ravaggi A, Rossini A, Radaeli E (1997) Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: different prognosis according to the immune status. Blood 90(3):1309?1314","journal-title":"Blood"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1537-2995.1997.37397240215.x","volume":"37","author":"Widell","year":"1997","unstructured":"Widell A, Zhang YY, Andersson-Gare B, Hammarstrom L (1997) At least three hepatitis C virus strains implicated in Swedish and Danish patients with intravenous immunoglobulin-associated hepatitis C. Transfusion 37(3):313?320","journal-title":"Transfusion"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0168-8278(05)80328-9","volume":"21","author":"Yap","year":"1994","unstructured":"Yap PL, McOmish F, Webster AD, Hammarstrom L, Smith CI, Bjorkander J et al (1994) Hepatitis C virus transmission by intravenous immunoglobulin. J Hepatol 21(3):455?460","journal-title":"J Hepatol"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1331\/108658002763316888","volume":"42","author":"Ballow","year":"2002","unstructured":"Ballow M (2002) Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharm Assoc (Wash) 42(3):458?459","journal-title":"J Am Pharm Assoc"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/cei.1996.104.s1.31","volume":"104","author":"Dodd","year":"1996","unstructured":"Dodd RY (1996) Infectious risk of plasma donations: relationship to safety of intravenous immune globulins. Clin Exp Immunol 104 (Suppl 1):31?34","journal-title":"Clin Exp Immunol"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1046\/j.1537-2995.1999.39111160.x","volume":"39","author":"Tabor","year":"1999","unstructured":"Tabor E (1999) The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39:1160?1168","journal-title":"Transfusion"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/S1246-7820(00)80009-9","volume":"7","author":"Barin","year":"2000","unstructured":"Barin F (2000) Viruses and unconventional transmissible agents: update on transmission via blood. Transfus Clin Biol 7 (Suppl 1):5S?10S","journal-title":"Transfus Clin Biol"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1423-0410.1998.7530178.x","volume":"75","author":"Will","year":"1998","unstructured":"Will RG, Kimberlin RH (1998) Creutzfeldt-Jakob disease and the risk from blood or blood products. Vox Sang 75(3):178?180","journal-title":"Vox Sang"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1423-0410.1998.tb05410.x","volume":"74","author":"Yap","year":"1998","unstructured":"Yap PL, Leaver HA, Gillon J (1998) Prions: properties, occurrence, modes of transmission and relevance for blood transfusion and blood derivatives. Vox Sang 74(Suppl 2):131?134","journal-title":"Vox Sang"},{"key":"CR28","unstructured":"Lacy CF, Armstrong LL, Goldman MP, Lance LL (2003) Drug Information Handbook, 11th ed. Hudson, Ohio, Lexi-Comp Inc"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"S449","DOI":"10.1093\/clinids\/8.Supplement_4.S449","volume":"8","author":"Schiff","year":"1986","unstructured":"Schiff RI (1986) Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity. Rev Infect Dis 8 (Suppl 4):S449?S456","journal-title":"Rev Infect Dis"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1212\/WNL.50.2.398","volume":"50","author":"Achiron","year":"1998","unstructured":"Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M et al (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50(2):398?402","journal-title":"Neurology"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0140-6736(96)09377-4","volume":"349","author":"Fazekas","year":"1997","unstructured":"Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349(9052):589?593","journal-title":"Lancet"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 41(6):789?796","journal-title":"Ann Neurol"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM198608073150601","volume":"315","author":"Newburger","year":"1986","unstructured":"Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE et al (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315(6):341?347","journal-title":"N Engl J Med"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","volume":"324","author":"Newburger","year":"1991","unstructured":"Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ et al (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633?1639","journal-title":"N Engl J Med"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.50.5.1273","volume":"50","author":"Sorensen","year":"1998","unstructured":"Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M et al (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50(5):1273?1281","journal-title":"Neurology"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"van der Mech\u00e9","year":"1992","unstructured":"van der Mech\u00e9 FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326(17):1123?1129","journal-title":"N Engl J Med"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/cei.1996.104.s1.55","volume":"104","author":"Dalakas","year":"1996","unstructured":"Dalakas MC (1996) Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol 104 (Suppl 1):55?60","journal-title":"Clin Exp Immunol"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","volume":"345","author":"Kazatchkine","year":"2001","unstructured":"Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345(10):747?755","journal-title":"N Engl J Med"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000073059","volume":"50","author":"Wittstock","year":"2003","unstructured":"Wittstock M, Benecke R, Zettl UK (2003) Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 50(3):172?175","journal-title":"Eur Neurol"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1056\/NEJM199107113250207","volume":"325","author":"Buckley","year":"1991","unstructured":"Buckley RH, Schiff RI (1991) The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 325(2):110?117","journal-title":"N Engl J Med"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00915419","volume":"7","author":"Bjorkander","year":"1987","unstructured":"Bjorkander J, Hammarstrom L, Smith CI, Buckley RH, Cunningham-Rundles C, Hanson LA (1987) Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 7(1):8?15","journal-title":"J Clin Immunol"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/archinte.154.17.1985","volume":"154","author":"Ahsan","year":"1994","unstructured":"Ahsan N, Palmer BF, Wheeler D, Greenlee RG Jr, Toto RD (1994) Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 154(17):1985?1987","journal-title":"Arch Intern Med"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0272-6386(95)90003-9","volume":"25","author":"Cantu","year":"1995","unstructured":"Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ (1995) Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 25(2):228?234","journal-title":"Am J Kidney Dis"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1093\/ndt\/13.9.2182","volume":"13","author":"Stahl","year":"1998","unstructured":"Stahl M, Schifferli JA (1998) The renal risks of high-dose intravenous immunoglobulin treatment [editorial]. Nephrol Dial Transplant 13(9):2182?2185","journal-title":"Nephrol Dial Transplant"},{"key":"CR45","unstructured":"US Food and Drug Administration. Important Drug Warning. http:\/\/www.fda.gov\/cber\/ltr\/igivrenal.htm"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0002-9343(87)90112-4","volume":"82","author":"Brox","year":"1987","unstructured":"Brox AG, Cournoyer D, Sternbach M, Spurll G (1987) Hemolytic anemia following intravenous gamma globulin administration. Am J Med 82 (Suppl 3):633?635","journal-title":"Am J Med"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0022-3476(05)81964-X","volume":"120","author":"Comenzo","year":"1992","unstructured":"Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM (1992) Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 120(6):926?928","journal-title":"J Pediatr"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1046\/j.1537-2995.1986.26587020113.x","volume":"26","author":"Copelan","year":"1986","unstructured":"Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ (1986) Hemolysis following intravenous immune globulin therapy. Transfusion 26(5):410?412","journal-title":"Transfusion"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000206033","volume":"76","author":"Nakamura","year":"1986","unstructured":"Nakamura S, Yoshida T, Ohtake S, Matsuda T (1986) Hemolysis due to high-dose intravenous gammaglobulin treatment for patients with idiopathic thrombocytopenic purpura. Acta Haematol; 76(2?3):115?118","journal-title":"Acta Haematol"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","volume":"121","author":"Sekul","year":"1994","unstructured":"Sekul EA, Cupler EJ, Dalakas MC (1994) Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 121(4):259?262","journal-title":"Ann Intern Med"},{"key":"CR51","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","volume":"47","author":"Brannagan","year":"1996","unstructured":"Brannagan TH, Nagle KJ, Lange DJ, Rowland LP (1996) Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47(3):674?677","journal-title":"Neurology"},{"key":"CR52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/000331970205300117","volume":"53","author":"Crouch","year":"2002","unstructured":"Crouch ED, Watson LE (2002) Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura?a case report and literature review. Angiology 53(1):113?117","journal-title":"Angiology"},{"key":"CR53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/ard.59.1.77","volume":"59","author":"Elkayam","year":"2000","unstructured":"Elkayam O, Paran D, Milo R, Davidovitz Y, Almoznino-Sarafian D, Zeltser D et al (2000) Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 59(1):77?80","journal-title":"Ann Rheum Dis"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1592\/phco.22.17.1638.34125","volume":"22","author":"Emerson","year":"2002","unstructured":"Emerson GG, Herndon CN, Sreih AG (2002) Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy 22(12):1638?1641","journal-title":"Pharmacotherapy"},{"key":"CR55","unstructured":"FDA: FDA Interim Statement Regarding Immune Globulin Intravenous (IGIV). http:\/\/www.fda.gov\/cber\/infosheets\/igiv082702.htm"},{"key":"CR56","first-page":"775","volume":"13","author":"Fisman","year":"1997","unstructured":"Fisman DN, Smilovitch M (1997) Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol 13(8):775?777","journal-title":"Can J Cardiol"},{"key":"CR57","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4065\/75.1.83","volume":"75","author":"Go","year":"2000","unstructured":"Go RS, Call TG (2000) Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 75(1):83?85","journal-title":"Mayo Clin Proc"},{"key":"CR58","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1212\/01.WNL.0000068334.04500.08","volume":"60","author":"Okuda","year":"2003","unstructured":"Okuda D, Flaster M, Frey J, Sivakumar K (2003) Arterial thrombosis induced by IVIg and its treatment with tPA. Neurology 60(11):1825?1826","journal-title":"Neurology"},{"key":"CR59","first-page":"115","volume":"43","author":"Struble","year":"2002","unstructured":"Struble EJ, Dice YG (2002) Intravenous immune globulin (IVIG) precipitating acute myocardial infarction. J Miss State Med Assoc 43(4):115","journal-title":"J Miss State Med Assoc"},{"key":"CR60","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1468-1331.2003.00542.x","volume":"10","author":"Zaidan","year":"2003","unstructured":"Zaidan R, Al Moallem M, Wani BA, Shameena AR, Al Tahan AR, Daif AK et al (2003) Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurol 10(4):367?372","journal-title":"Eur J Neurol"},{"key":"CR61","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A et al (2002) Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirtyfive adult patients. Arthritis Rheum 46(2):467?474","journal-title":"Arthritis Rheum"},{"key":"CR62","first-page":"29","volume":"10","author":"G\u00f6ttfried","year":"2000","unstructured":"G\u00f6ttfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B (2000) High-dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 10(1):29?35","journal-title":"Eur J Dermatol"},{"key":"CR63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.61.1.37","volume":"61","author":"Danieli","year":"2002","unstructured":"Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M et al (2002) Cyclosporin A and intravenous immunoglobulin treatment in polymyositis\/dermatomyositis. Ann Rheum Dis 61(1):37?41","journal-title":"Ann Rheum Dis"},{"key":"CR64","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.43.5.876","volume":"43","author":"Soueidan","year":"1993","unstructured":"Soueidan SA, Dalakas MC (1993) Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 43(5):876?879","journal-title":"Neurology"},{"key":"CR65","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.58.2.326","volume":"58","author":"Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S et al (2002) Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58(2):326","journal-title":"Neurology"},{"key":"CR66","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.7326\/0003-4819-134-12-200106190-00031","volume":"134","author":"Mukunda","year":"2001","unstructured":"Mukunda BN, Dileep Kumar P, Smith HR (2001) Long-lasting effectiveness of intravenous immunoglobulin in a patient with inclusion-body myositis. Ann Intern Med 134(12):1156 (letter)","journal-title":"Ann Intern Med"},{"key":"CR67","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1212\/WNL.44.8.1516","volume":"44","author":"Amato","year":"1994","unstructured":"Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT (1994) Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 44(8):1516?1518","journal-title":"Neurology"},{"key":"CR68","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIG: a double-blind, placebo-controlled study. Neurology 48(3):712?716","journal-title":"Neurology"},{"key":"CR69","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"56","author":"Dalakas","year":"2001","unstructured":"Dalakas MC, Koffman BM, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56(3):323?327","journal-title":"Neurology"},{"key":"CR70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"Walter","year":"2000","unstructured":"Walter MC, Lochm\u00fcller H, T\u00f6pfer M, Schlotter B, Reilich P, Schr\u00f6der M et al (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247(1):22?28","journal-title":"J Neurol"},{"key":"CR71","first-page":"2143","volume":"21","author":"Pelkonen","year":"1994","unstructured":"Pelkonen PM, Jalanko HJ, Lantto RK, Makela AL, Pietikainen MA, Savolainen HA et al (1994) Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol 21(11):2143?2146","journal-title":"J Rheumatol"},{"key":"CR72","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/archsurg.1988.01400330093014","volume":"123","author":"Downey","year":"1988","unstructured":"Downey ECJr, Woolley MM, Hanson V (1988) Required surgical therapy in the pediatric patient with dermatomyositis. Arch Surg 123(9):1117?1120","journal-title":"Arch Surg"},{"key":"CR73","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/000992288702601101","volume":"26","author":"Miller","year":"1987","unstructured":"Miller LC, Michael AF, Kim Y (1987) Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr (Phila) 26(11):561?566","journal-title":"Clin Pediatr"},{"key":"CR74","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1542\/pir.12-4-117","volume":"12","author":"Pachman","year":"1990","unstructured":"Pachman LM (1990) Juvenile dermatomyositis: a clinical overview. Pediatrics in Review 12(4):117?125","journal-title":"Pediatrics in Review"},{"key":"CR75","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T","volume":"43","author":"Huber","year":"2000","unstructured":"Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P et al (2000) Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43(3):541?549","journal-title":"Arthritis Rheum"},{"key":"CR76","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1525-1470.1996.tb00728.x","volume":"13","author":"Quecedo","year":"1996","unstructured":"Quecedo E, Febrer I, Serrano G, Martinez-Aparicio A, Aliaga A (1996) Partial lipodystrophy associated with juvenile dermatomyositis: report of two cases. Pediatr Dermatol 13(6):477?482","journal-title":"Pediatr Dermatol"},{"key":"CR77","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02230347","volume":"15","author":"Galeazzi","year":"1996","unstructured":"Galeazzi M, Bellucci AM, Girardelli CR, Bono R, De Pita O, Puddu P (1996) Efficacy of intravenous immunoglobulin therapy in a case of juvenile dermatomyositis. Clin Rheumatol 15(2):215?216","journal-title":"Clin Rheumatol"},{"key":"CR78","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1046\/j.1442-200x.1999.01132.x","volume":"41","author":"Kokori","year":"1999","unstructured":"Kokori H, Fotoulaki M, Giannakopoulou C, Hatzidaki E, Tantros S, Sbyrakis S (1999) Intravenous immunoglobulin treatment in a girl with juvenile dermatomyositis. Pediatr Int 41(6):696?697","journal-title":"Pediatr Int"},{"key":"CR79","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.1987.03400040111034","volume":"258","author":"Roifman","year":"1987","unstructured":"Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW (1987) Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 258(4):513?515","journal-title":"JAMA"},{"key":"CR80","first-page":"1979","volume":"137","author":"Breems","year":"1993","unstructured":"Breems DA, de Haas PW, Visscher F, Sabbe LJ, Busch HF, van Doorn PA (1993) Intravenously-administered immunoglobulin as first-choice agent in juvenile dermatomyositis. Ned Tijdschr Geneeskd 137(39):1979?1982","journal-title":"Ned Tijdschr Geneeskd"},{"key":"CR81","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2133.1994.tb02906.x","volume":"130","author":"Collet","year":"1994","unstructured":"Collet E, Dalac S, Maerens B, Courtois JM, Izac M, Lambert D (1994) Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol 130(2):231?234","journal-title":"Br J Dermatol"},{"key":"CR82","first-page":"523","volume":"21","author":"Morita","year":"1989","unstructured":"Morita R, Nakano K, Hirano Y, Izumi T, Hirayama Y, Suzuki H et al (1989) Dramatic effects of high-dose intravenous gammaglobulin in each patient with intractable dermatomyositis and polymyositis. No To Hattatsu 21(6):523?528","journal-title":"No To Hattatsu"},{"key":"CR83","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s001050050185","volume":"45","author":"Schmidt","year":"1994","unstructured":"Schmidt K, Westenberger-Treumann M, Stadler R (1994) High dosage intravenous gamma globulin therapy in juvenile dermatomyositis. Hautarzt 45(12):854?857","journal-title":"Hautarzt"},{"key":"CR84","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0887-8994(95)00195-6","volume":"13","author":"Vedanarayanan","year":"1995","unstructured":"Vedanarayanan V, Subramony SH, Ray LI, Evans OB (1995) Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin. Pediatr Neurol 13(4):336?339","journal-title":"Pediatr Neurol"},{"key":"CR85","first-page":"522","volume":"107","author":"Zifko","year":"1995","unstructured":"Zifko U, Grisold W (1995) Dermatomyositis: Erfolgreiche Therapie mit hochdosierten intraven\u00f6s applizierten 7S-Immunoglobulinen. Wien Klin Wochenschr 107(17):522?524","journal-title":"Wien Klin Wochenschr"},{"key":"CR86","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0002-9343(91)90010-U","volume":"91","author":"Lang","year":"1991","unstructured":"Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM (1991) Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 91(2):169?172","journal-title":"Am J Med"},{"key":"CR87","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/adc.72.1.25","volume":"72","author":"Samsone","year":"1995","unstructured":"Samsone A, Dubowitz V (1995) Intravenous immunoglobulin in juvenile dermatomyositis?four year review of nine cases. Arch Dis Child 72(1):25?28","journal-title":"Arch Dis Child"},{"key":"CR88","first-page":"2498","volume":"27","author":"Al-Mayouf","year":"2000","unstructured":"Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM (2000) Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27(10):2498?2503","journal-title":"J Rheumatol"},{"key":"CR89","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1212\/WNL.51.6_Suppl_5.S37","volume":"51","author":"Dalakas","year":"1998","unstructured":"Dalakas MC (1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51 (Suppl 5)(6 Suppl 5):S37?S45.","journal-title":"Neurology"}],"container-title":["Zeitschrift f\ufffdr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-005-0695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-005-0695-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-005-0695-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T18:27:53Z","timestamp":1683052073000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-005-0695-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1007\/s00393-005-0695-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}